English
Mahasweta Gooptu
121 posts
Mahasweta Gooptu
@MGooptu
Adult BMT Faculty at Dana-Farber Cancer Institute Assistant Professor of Medicine, Harvard Medical School Interests: Allogeneic transplantation
Boston Katılım Şubat 2020
107 Takip Edilen153 Takipçiler
Excited to share I will be joining @DanaFarber as their 2027 Advanced BMT fellow 🥳🫣
Thank you to my mentors @MayoHemeOnc and @ash CRTI for the incredible support!
Incredibly appreciative of Drs Gooptu, @DrCCutler, Soiffer & Antin for the vote of confidence… CAN’T WAIT!! 🎉🎉
English
Congratulations Moses!! Rising star at DFCI @haematognomist @DanaFarberNews
ASTCT@ASTCT
Award Spotlight: Learn more about H. Moses Murdock, MD, recipient of the ASTCT New Investigator Award, who discusses working toward safe and effective post-transplant maintenance therapies. Read more in Tandem Meeting News: ow.ly/fQ5G50Y9q2J
English
@haematognomist Congratulations on your new investigator award!! Rising star at DFCI @DanaFarberNews
ASTCT@ASTCT
Award Spotlight: Learn more about H. Moses Murdock, MD, recipient of the ASTCT New Investigator Award, who discusses working toward safe and effective post-transplant maintenance therapies. Read more in Tandem Meeting News: ow.ly/fQ5G50Y9q2J
English
Amazing team effort and leadership!! @DrCCutler
Dana-Farber@DanaFarber
We’re thrilled that both our adult and pediatric stem cell/bone marrow transplant programs earned the highest possible +1 score in the 2025 @CIBMTR Survival Report — exceeding expected 1-year survival nationwide. Thank you to our dedicated team and partners for advancing patient care every day. Learn more: bit.ly/4pHA7EJ
English
80% 1 year overall survival in mismatched unrelated donor transplants all the way down to 4/8 mismatched donors!! #Donorsforall #solvedisparitieswithscience @BrianShafferMD @BronwenShaw @nmdp_org
Dana-Farber News@DanaFarberNews
Dr. Mahasweta Gooptu (@MGooptu) @danafarber &@nmdp_org presented results using post-transplant cyclophosphamide to prevent graft-versus-host disease in mismatched unrelated donor transplantation, with about 80% 1-year survival thus expanding access to allotransplant for all patients. #ASH25
English
Mahasweta Gooptu retweetledi
CONGRESS | #ASH2025 | POSTER
Mahasweta Gooptu shares results from a Phase II expansion study focusing on PTCy-based GVHD prophylaxis after MMUD PBSC transplantation with reduced-intensity conditioning (N = 193).
The 1-year OS estimate was 79.6%; rates were comparable between HLA 7/8-matched donor recipients and <7/8 matched donor recipients. The 1-year GRFS, 1-year PFS, 1-year CI rate of NRM, and 1-year CI rate of relapse was 49.9%, 70.2%, 12.5%, and 17.3%, respectively.
Follow our live feed for more updates: loom.ly/MbPzIiA
Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content. A full list of supporters can be found on our website.
#GvHD #GvHDsm #MedEd #MedicalCongress @MGooptu @DanaFarber
English
Mahasweta Gooptu retweetledi
Donor selection guidelines are out! Grateful to have worked with amazing colleagues and the @CIBMTR and @nmdp_org on this effort. Advances in GVHD prophylaxis support moving beyond strict HLA models toward an integrated approach that brings us closer to a suitable donor for every patient. #ADonorForAll #PTCyRules
CIBMTR@CIBMTR
Just Published in @ASTCT_Journal: Allogeneic Hematopoietic Cell Donor Selection: Contemporary Guidelines from the NMDP/CIBMTR. Read more: sciencedirect.com/science/articl…
English
Mahasweta Gooptu retweetledi
English
@nursariipek @NalanYurtsever1 @YaleIMed @ProjectImg @StoriesImg @IMG_Oncologists @TheNRMP @Ankaratip1945 @IMG_Advocate Wonderful news! Congratulations :)
English
Almost three years ago, @NalanYurtsever1 got accepted to the transfusion fellowship at Yale, and as my first mentor, I celebrated by baking her a cake. Today, I’m beyond thrilled to share that I matched at @YaleIMed for my residency!!
I am endlessly grateful to all my incredible mentors—Drs. @vangalenlab, DeAngelo, @MaxStahlMD, @Dr_AmerZeidan, @MullallyLab, @DrYukselUrun, Battinelli, Berliner, @MGooptu, @lane_andy, @BusemBKurt, @NazliDizman, and so many more—who have guided, supported, and inspired me along this journey.
Dear Dr. @MarkDSiegel1, thank you for believing in me! I can’t wait to join the Yale family and start this next chapter! 💙🎉 #Match2025
English
Mahasweta Gooptu retweetledi
India’s first indigenous CAR-T therapy is now peer-reviewed in @TheLancetHaem , showing a 73% response rate—marking a breakthrough in accessible, cutting-edge cancer treatment.
English
Mahasweta Gooptu retweetledi
Congratulations to @DanaFarber researcher Joseph H. Antin, MD, who received the @ASTCT Lifetime Achievement Award during #Tandem25. He was honored for his ongoing contributions to cellular therapy by advancing scientific knowledge in the field.
English
Mahasweta Gooptu retweetledi
Congratulations to Joseph Antin, MD, recipient of the @ASTCT Lifetime Achievement Award. This recognition is given to a physician who has made continuing contributions to the BMT and cellular therapy fields through the advancement of knowledge through basic or clinical science.
bit.ly/3X05jmp
English
English
English
What do you say when you are recognized for doing what you love? Thank you, @ASTCT! I am beyond grateful to my patients and colleagues, many of whom joined in the festivities tonight. Thank you so much! ❤️
ASTCT@ASTCT
Congratulations to @sghmd, the 2025 recipient of the Lukas D. Wartman GVHD Achievement Award. #Tandem25
English
Contributions that cannot be quantified..one of the true pioneering giants in transplantation !! Congratulations Joe Antin :). @DrCCutler @DanaFarberNews
Jeff Auletta@JeffAuletta
Congratulations, Dr. Antin as @ASTCT Lifetime Achievement Award! Well deserved! 2025 @ASTCT @CIBMTR Tandem Meetings #Tandem25
English
Mahasweta Gooptu retweetledi
Asciminib plus dasatinib and prednisone for Philadelphia chromosome–positive acute leukemia ashpublications.org/blood/article-…
by Dr. Luskin et al. #leusm #ALL
100% CR.
At day 84, 100% of patients achieved complete cytogenetic remission.
At day 84, 74% and 26% achieved BCR::ABL1 reverse transcription quantitative polymerase chain reaction <0.1% and <0.01%, respectively.
English
@MediHumdani I so feel your pain! This could be my clinic tomorrow. We are living the good life :D
English
People wonder why physicians #burnout
Evidence below:
Plus do you are expected to do more:
- research
- administration
- teaching
- nonsense satisfaction score (FYI patients want doctors to talk to them. How do you do that when you are double triple booked???)
English